Stage IV Squamous Cell Lung Carcinoma AJCC v7 Active Not Recruiting Phase 2 Trials for Talazoparib (DB11760)

IndicationStatusPhase
DBCOND0092102 (Stage IV Squamous Cell Lung Carcinoma AJCC v7)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03377556Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung CancerTreatment